Consistently, the plasma FGL1 levels were significantly higher in cancer patients than in healthy donors, and the levels were also significantly increased in metastatic CRC or GC patients compared with patients without liver metastases (Fig. 2E, F, S2A). Here, FGL1 is linked to cancer.